Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
|Videos|November 6, 2021
An In-depth Look into Regional Dermatitis and Rash
Author(s)Mary Scoviak, Managing Editor
In this video interview, Jeff Yu, MD, highlights key talking points from his session on regional dermatitis and rash from the American College of Allergy, Asthma & Immunology annual scientific meeting.
Advertisement
Jeff Yu, MD, is a board-certified dermatologist and fellowship trained pediatric dermatologist specializing in allergic contact dermatitis at the Massachusetts General Hospital for children, Boston, Massachusetts.
In this video, he explains possible trigger for regional dermatitis, how it affects patients lives, and how he thinks the field could be improved.
Advertisement
Related to this article
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
4
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
5